InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing ...
JENA, Deutschland – InflaRx N.V. (NASDAQ:IFRX) hat laut einer Pressemitteilung auf der Jahrestagung der American Academy of ...
Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the ...
InflaRx (IFRX) is a developer of complement mediated therapies for inflammatory diseases. The complement system is described by the company as follows: The complement system, also known as complement ...
Darin hatten 13 Patienten mit Pyoderma gangraenosum (Dermatitis ulcerosa) randomisiert und doppelblind eine einmalige Infusion mit 5 mg/kg des TNF-alpha-Blockers Infliximab (Remicade®) erhalten. 17 ...
Das lässt sich aus einer retrospektiven multizentrischen Studie schließen, in der Dr. Philipp Al Ghazal aus Essen Daten von 259 Patienten mit Pyoderma gangraenosum aus 21 deutschen Hautkliniken ...
Ein 72-jähriger Patient stellte sich in unserer Klinik mit seit zehn Jahren rezidivierenden Ulzerationen am rechten Gaumenbogen vor. In der Vergangenheit war eine Exzision der Läsion erfolgt, die ein ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results